Oncology Leaders Address Testing, Access, Equity, and Pharmacy in Cancer Care

Why It Matters

Streamlined testing and in‑house pharmacy models improve patient outcomes while lowering operational costs, positioning health systems for sustainable value‑based oncology delivery.

Key Takeaways

• Universal lung cancer biomarker testing advocated for all disease stages
• Illinois HB 1779 mandates coverage for evidence‑based molecular tests
• AI assists sequencing labs in fusion‑gene interpretation
• CAR‑T therapy faces 2‑month Medicaid approval, limiting access
• Integrated oncology pharmacies cut prior‑auth time by ~50% and lower drug costs

Pulse Analysis

Precision oncology’s rapid evolution has outpaced many health‑system operations, making coordinated testing pathways a competitive differentiator. In Chicago, leaders argued that molecular profiling should be a reflex order for every lung‑cancer patient, not just those with advanced disease. The integration of next‑generation sequencing into electronic health records has slashed order times from up to ten minutes to under two, while state legislation like Illinois HB 1779 guarantees reimbursement for evidence‑based assays. Yet regulatory quirks such as the 14‑day rule still delay critical decisions for in‑patients, prompting work‑arounds that blend liquid biopsies with real‑time order tracking.

Hematologic malignancies present a parallel set of operational bottlenecks, from incomplete test requisitions to uneven adoption of minimal residual disease monitoring. Laboratories are turning to artificial‑intelligence platforms to accelerate fusion‑gene detection, a move that could standardize interpretations across institutions. However, access to high‑cost therapies remains uneven; Medicaid’s two‑month CAR‑T approval process and gaps in TP53 testing reimbursement force many patients toward bispecific antibodies, underscoring how payer policies shape clinical pathways. Financial toxicity extends beyond drugs, as premature release of complex genomic reports can generate anxiety and additional provider workload.

Medically integrated dispensing (MID) models are emerging as a pragmatic solution to these challenges. By embedding specialty pharmacists within the health‑system, institutions like Northwestern and Rush have reduced prior‑authorization turnaround from three‑plus days to roughly two, a 50 % efficiency gain, while also negotiating in‑house compounding that cuts patient out‑of‑pocket costs—from $155 to $40 in a recent case. MID also streamlines adverse‑event monitoring, enabling pharmacists to intervene early and keep patients on schedule. As payers expand site‑of‑care restrictions, health systems that can demonstrate cost‑effective, patient‑centric pharmacy operations will be better positioned to negotiate contracts and sustain value‑based oncology programs.